Anthony Hall work email
- Valid
- Valid
- Valid
Anthony Hall personal email
Anthony Hall phone numbers
An experienced pharmaceutical physician with knowledge spanning a broad range of disciplines and therapy areas. Having founded and built my own successful company, I have a demonstrated ability to lead, inspire and motivate, together with keen strategic vision and commercial acumen.From 2010 – 2014, I worked as a consultant exclusively on Orphan drugs and became heavily involved with all facets of the rare diseases community, regularly speaking at conferences. I have built trusted relationships with stakeholders at many different levels, including patient groups, key opinion leaders and academics. I have gained significant experience in drug development for orphan drugs, from understanding the special regulatory requirements applicable for orphan drugs to designing the clinical programs to meet them.I am very interested in clinical endpoint development, including surrogate endpoints and in innovative drug development pathways, such as adaptive licensing with the involvement of all stakeholders, including payers at an early stage.I graduated from King’s College London with first class honours in physiology and pharmacology before going on to study medicine at the Royal Free Hospital, London.Specialties: Rare diseases;Orphan Drugs;Clinical Development planning;Medical & regulatory drug development expertise; Company start-up expertise
-
Chief Medical OfficerBoost PharmaUnited Kingdom
-
Independent ConsultantRare Diseases Nov 2024 - Present
-
Co-Founder, Member Of Board Of Trustees And Scientific AdvisorBeacon For Rare Diseases Jun 2012 - PresentCambridge, Cambridgeshire, GbFindacure is a charity with the mission to build a movement to promote research and development of treatments for fundamental diseases on behalf of patients and those who care for them. We do this by: ● Empowering patient groups to evolve into effective campaigners for change. ● Facilitating patient groups to drive the development of treatments for fundamental diseases. ● Campaigning for a receptive research environment that recognises the pivotal importance of fundamental diseases. In undertaking our mission, Findacure follows in the footsteps of William Bateson, the father of modern genetics, who reminded us that it is worthwhile to "treasure our exceptions". Fundamental diseases are extreme and rare genetic disorders, which offer a unique opportunity to better understand other diseases, including many common conditions. We have coined this term in order to emphasise the fact that rare diseases are relevant for everyone, not only those people who are affected by them. This paradigm is more relevant today than ever, but has been recognised for centuries, as exemplified by this quote from Dr William Harvey in 1657: “There is no better way to advance the proper practice of medicine than to give our minds to the discovery of the usual law of nature by the careful investigation of cases of rarer forms of disease.” -
Chief Medical OfficerSirgartan Therapeutics May 2024 - Nov 2024Sirgartan believes that mental illness should no longer be underestimated and stigmatised. Sirgartan Therapeutics is a drug development company established in 2020 and poised to enter the clinic in 2024. Our vision is to transform the treatment paradigm for OCD (obsessive compulsive disorder) and deliver life-changing medicines for patients with this condition, many of whom are very poorly treated with current therapies.The company is working with the University of Cambridge, UK on a first-in-class treatment based on modulation of glutamate. The development asset was recently taken to clinical trials for another condition, but then discontinued due to lack of efficacy in that condition, leaving Sirgartan able to use the existing information to shortcut entry into clinical trials for OCD.Investment obtained through initial seed-funding has enabled advanced pre-clinical studies to be carried out by the University of Cambridge. These studies have shown very encouraging results in an animal model of OCD, much to the satisfaction of Professor Trevor Robbins, Chief Scientific Advisor to Sirgartan, and to the recent submission of a patent application for the identified therapy and its method of action.The company is now seeking further funding to enable progression into clinical studies. Please contact us should you or your organisation have an interest in joining us on this journey.
-
Chief Medical OfficerHealx Jan 2020 - Apr 2024Cambridge, Cambridgeshire, Gb -
Member Of Scientific Advisory BoardDuchenne Uk Feb 2014 - Feb 2023London, Gb -
Chief Medical OfficerAparito Jul 2019 - Dec 2019Wrexham, Wales, GbAparito links wearable devices with disease-specific mobile apps to provide remote patient monitoring outside of the hospital environment. This delivers meaningful, relevant, and real-time data between patients and clinicians in a way that actively supports and enhances diagnosis and treatment. This helps to support better patient outcomes, improve understanding of disease, and clinical trial outcomes, facilitating innovative drug development, particularly for rare (orphan) diseases and paediatrics. -
On SabbaticalN/A Dec 2018 - Jul 2019An incredible 6-month round the world adventure.
-
Therapeutic Area Head Orphan DrugsMereo Biopharma Nov 2015 - Jul 2019London, GbMereo has acquired a human anti-sclerostin monoclonal antibody, with the intention to develop it for the treatment of osteogenesis imperfecta (OI).I am responsible for all aspects of this development programme. -
Real World Data Working Group - Committee MemberFaculty Of Pharmaceutical Medicine Apr 2017 - Apr 2019London, London, Gb -
Co-Founder & ShareholderPsr: The Orphan Drug Experts Jun 2001 - Sep 2017Hoofddorp, Nl -
Chief Executive OfficerPsr: The Orphan Drug Experts Jun 2001 - Dec 2009Hoofddorp, NlI was one of the founders of the company, which I ran for 8 years before stepping out of the day-to-day management in order to concentrate on the Findacure charity and my consultancy work.
-
Group Medical DirectorBiomarin Nederland B.V. Jul 2015 - Oct 2015• Recruit and lead a team of medics for the Neuromuscular business;• Accountability for the strategic planning and execution of clinical trial programmes;• Provide clinical expertise for the R&D projects under my care;• Serve as the Medical Monitor for clinical trials;• Collaborate with internal & external stakeholders to ensure successful implementation of projects;• Serve as medical and technical resource for clinical issues raised by internal and external collaborators, investigators, consultants and contract resources;• Participate in the pharmacovigilance process;• Participate in analysis and interpretation of interim and final study data.
-
Medical Director Medical AffairsBiomarin Nederland B.V. Aug 2014 - Jun 2015I provide medical expertise to the global drug development process and commercial organization with an emphasis on late phase studies. I also provide a strategic lead to the label extension studies for drisapersen and direction and leadership to clinical project managers by acting as Medical Monitor.I work closely with commercial colleagues, providing medical input in preparation for launch and post marketing activities for drisapersen. This includes training of staff, advising on appropriate clinical trial activities, expanded access and registry studies, KOL interactions and visibility on the company booth at scientific meetings.I work closely with the patient advocacy staff, regularly being the company spokesperson at patient group meetings, helping to maintain our relationships with the patient community.
-
Chief Medical OfficerDcprime Oct 2012 - Dec 2013DCPrime develops dendritic cell-based vaccines for a broad range of cancer types, based on its unique, proprietary technology platform, DCOne™. This first-in-class platform combines the power of dendritic cell-based vaccines with the advantages of allogeneic stimulation of the immune system whilst bypassing the complex logistics of autologous DC vaccines. The company’s lead product DCP-001 is in Phase I/IIa in patients with Acute Myeloid Leukemia (AML). A Phase II efficacy study will start shortly. Several products for solid cancers are in preclinical development, using peptide loaded DCOne-based vaccines.
-
Senior Clinical Research ManagerYamanouchi Nov 1999 - Jun 2001As the medical member of the European Project Team, I was responsible for the “hands-on” management of ongoing clinical trials and the design and implementation of new studies. I was involved in safety assessments, addressing questions from the regulatory authorities, the supervision of writing of clinical trial reports and the writing of Clinical Expert Reports.I was responsible for the conception and implementation of the clinical development plan for a combination product with the new device. -
Team Member MedicineBoehringer Ingelheim Aug 1998 - Oct 1999Ingelheim Am Rhein, Rhineland-Palatinate, DeAn international role with global responsibility for all medical aspects of the product, from the clinical development planning to the overall safety of the product. I was responsible for medical support to regulatory, including the handling of questions from the regulatory authorities.I provided medical support to Corporate Marketing during the launch phase. This included helping to develop promotional material, product monographs and training manuals, manuscripts for publication, opinion leader support, presentation of product features at advisory board meetings and internal medico-marketing meetings.I developed a creative phase IV strategy and the supervised ongoing phase IIIb trials.I was also responsible for the clinical development plan for a fixed-dose combination product. -
Senior Medical AdviserBoehringer Ingelheim Apr 1994 - Aug 1998Ingelheim Am Rhein, Rhineland-Palatinate, DeSole responsibility for all aspects of phase IV activities for cardiovascular products. Responsible for new strategies in phase IV development and implementation of the clinical trial programs. Conceived and set clinical trials in the areas of hypertension, angina and myocardial infarction. Took on several international roles as Medical Sub-Team member for lacidipine and international Team Member Medicine for dipyridamole.Involved in the development of opinion leader support in the areas of hypertension, myocardial infarction and stroke. Responsible for the medico-marketing input into the launch phase of a combination product, dipyridamole/aspirin, for secondary prevention of stroke. Also helped to develop pre-launch strategies with a thrombolytic for the treatment of acute ischaemic stroke.
Anthony Hall Skills
Anthony Hall Education Details
-
Royal Free Hospital School Of MedicineMedicine -
King'S College LondonPhysiology & Pharmacology
-
Windsor Grammar School
-
Windsor College
-
Windsor College
Frequently Asked Questions about Anthony Hall
What company does Anthony Hall work for?
Anthony Hall works for Boost Pharma
What is Anthony Hall's role at the current company?
Anthony Hall's current role is Chief Medical Officer.
What is Anthony Hall's email address?
Anthony Hall's email address is to****@****oup.com
What is Anthony Hall's direct phone number?
Anthony Hall's direct phone number is +31 23 556*****
What schools did Anthony Hall attend?
Anthony Hall attended Royal Free Hospital School Of Medicine, King's College London, Windsor Grammar School, Windsor College, Windsor College.
What skills is Anthony Hall known for?
Anthony Hall has skills like Clinical Development, Clinical Trials, Pharmaceutical Industry, Drug Development, Regulatory Affairs, Clinical Research, Biopharmaceuticals, Medicine, Cro, Therapeutic Areas, Biotechnology, Gcp.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial